[go: up one dir, main page]

EP0565658A1 - Utilisation de la verbenone et de ses proprietes anti-elastase dans le traitement de l'emphyseme pulmonaire - Google Patents

Utilisation de la verbenone et de ses proprietes anti-elastase dans le traitement de l'emphyseme pulmonaire

Info

Publication number
EP0565658A1
EP0565658A1 EP92920465A EP92920465A EP0565658A1 EP 0565658 A1 EP0565658 A1 EP 0565658A1 EP 92920465 A EP92920465 A EP 92920465A EP 92920465 A EP92920465 A EP 92920465A EP 0565658 A1 EP0565658 A1 EP 0565658A1
Authority
EP
European Patent Office
Prior art keywords
verbenone
activity
pulmonary emphysema
medicament
solutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92920465A
Other languages
German (de)
English (en)
Inventor
Gerardo Bernasconi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flarer Pharmaceutical Fine Chemicals SA
Original Assignee
Flarer Pharmaceutical Fine Chemicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flarer Pharmaceutical Fine Chemicals SA filed Critical Flarer Pharmaceutical Fine Chemicals SA
Publication of EP0565658A1 publication Critical patent/EP0565658A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the use of a terpene derivative, namely (IS) (-)-4,6,6- trimethylbicyclo-(3,1,1)-hept-3-ene-2-one (hereinafter named verbenone) of formula
  • the invention also relates to a verbenone-cyclodextrin complex and the pharmaceutical compositions containing it.
  • Pulmonary emphysema is a progressive respiratory disorder characterized by an abnormal and permanent increase in the volume of the air spaces located distally to the terminal bronchiole, with destruction of the alveolar septum.
  • a number of experimental and clinical data generally ascribe the emphysema pathogenesis to an unbalance of the protease-antiprotease ratio at the alveolus level.
  • alveolar proteases exert an essential activity, which is the lysis of cell fragments, thrombi and particles. Said activity is counterbalanced be endogenous antiproteases (£ ⁇ -l antitrypsin [o lAT], ( -2 macroglobulin [ ⁇ -2M] , Bronchial Mucus Inhibitor [B.M.I.]), which protect the pulmonary tissue from the protease action.
  • the loss of the normal balance between proteases and antiproteases can be attributed to three factors: 1) congenital lack in antiproteases (particularly f ⁇ -lAT); 2) excessive protease release at the alveolus level; 3) partial inactivation of antiproteases (Ck-1AT) in the presence of a normal or enhanced protease production. Said factors are generally worsened by tobacco smoke.
  • alveolar proteases leukocytal elastase proves to have the most marked digestive activity on all the pulmonary connective components, particularly on elastin, the fibres of which constitute the alveolar septa, thus giving lung the functional elasticity.
  • verbenone exerts an unpredictable antielestase activity at the lung level, and, due to said activity, it is useful in the treatment of emphysema.
  • Verbenone is a monoterpene derivative having antiinflammatory and mucolytic activities and it is used as a mucolytic and fluidifying agent in the acute and chronic disorders of the respiratory tract.
  • verbenone showed a surprising inhibiting activity on the elastase action, particularly on the neutrophylic one. Said activity was unforeseeable from the pharmacological and clinical studies which evidenced the mucolytic and antiinflammatory activities of verbenone and the use thereof in therapy.
  • pulmonary emphysema can be favoured, or worsened, by the simultaneous presence of other pulmonary disorders, such as bronchitis and/or pneumonia, other infective forms, asthma, which involve obstructions of the respiratory tract; therefore a medicament which can at the same time have antiinflammatory and mucolytic activities and protect elastin of the alveolar septa is obviously useful.
  • Tests were carried out ⁇ n vitro to evaluate verbenone activity on the release of neutrophilic elastin from polymorphonuclear granules. Said tests evidenced the marked antielastase activity of verbenone, which activity is not dose-related nor cytotoxic.
  • Polymorphonuclear phagocytes were separate starting from heparinized peripheral blood (60 cc) fro healthy volunteers or from buffy coats (leukocytes an platelets enrichments).
  • Neutrophilic polymorphonuclears were separated b means of a 6% colloidal dextran gradient, then the erythrocytes were lysated with an ammonium chloride solution. Neutrophilic elastase release
  • the plate was centrifuged and 100 ⁇ l of supernatant were collected and incubated for 60-120' at 37 ⁇ C with a specific substrate for the neutrophilic elastase (methoxysuccinyl-ala-ala-pro-val-p-Na) to a 1 mM final concentration.
  • the reaction was stopped by adding 50 ⁇ l of 1 N acetic acid and reading was carried out by means of a multiscan photometer at a 405 nm wave length.
  • the values of the absorbance of samples challenged with fMLP were compared to those from unchallenged cells, to obtain a ⁇ value corresponding to the amount of neutrophilic elastase released following to challenge. Any interferences of verbenone on the neutrophilic elastase release were tested by addition of different concentrations of the medicament directly to the cell suspension during the test. The results are shown in Table 1.
  • verbenone is used as the active ingredient for the preparation of a medicament useful for the treatment of pulmonary emphysema.
  • verbenone has the drawbacks to be insoluble in water and to have a very unpleasant taste, therefore it cannot be used for aqueous liquid pharmaceutical forms, such as syrups, oral solutions, nasal drops, aqueous solutions for aerosol and nebulization.
  • the verbenone-cyclodextrin complex has high water solubility and, moreover, verbenone unpleasant taste is no more perceptible. Therefore, the verbenone-cyclodextrin complex is a further object of invention.
  • a further advantage of the complex of the invention is provided by its increased bioavailability.
  • the pharmaceutical forms comprising the verbenone- cyclodextrin complex can be prepared, for example, according to the methods described in "Remington's Pharmaceutical Sciences Handbook", Ralph Pub. Co., USA.
  • Examples of pharmaceutical forms are capsules, pills, tablets, sugar-coated pills, granulates, syrups, drinkable solutions, nasal drops, solutions for aerosol or inhalation, suppositories, injectable solutions or suspensions both for the intravenous and the intramuscular routes.
  • the dosages will depend on the severity of the disorder, the age, weight and sex of the patient and on the clinician's advise.
  • Examples of dosages comprise single or repeated administrations of the medicament containing verbenone or the verbenone-cyclodextrin complex so as to attain a daily dosage from 10 to 500 mg of the active ingredient.
  • the preparation of the verbenone-cyclodextrin complex is illustrated in the following examples.
  • a ⁇ -ciclodextrin amount equal to 0.1 mole is weighed and placed into a mortar of suitable size.
  • the obtained complex is in form of a flowing powder which is completely odourless.
  • the obtained product is an equimolar mixture (1:1) of verbenone and cyclodextrin (50 g theoretical, 49 g found).
  • ⁇ -Cyclodextrin ⁇ -Cyclodextrin are dispersed in 500 ml of distilled water (50 mmoles) and the solution is heated to 65 e C. under stirring, until complete dissolution. solution, with stirring. The mixture is left to cool t room temperature with stirring for 60 minutes, then i is kept at +4°C for 6 hours.
  • the solid phase is recovered by filtration and th solid is placed into a convection oven at 40°C for 18 hours, to obtain 64 g of a white powdery product, containing from 11.3 to 12.0% w/w of L-verbenone. Yield - 84.65%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

On décrit l'utilisation d'un dérivé du terpène dans la préparation d'un médicament qui est utile pour le traitement de l'emphysème pulmonaire.
EP92920465A 1991-10-04 1992-09-30 Utilisation de la verbenone et de ses proprietes anti-elastase dans le traitement de l'emphyseme pulmonaire Withdrawn EP0565658A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI912652 1991-10-04
ITMI912652A IT1251615B (it) 1991-10-04 1991-10-04 Medicamento ad attivita' antielastasica.

Publications (1)

Publication Number Publication Date
EP0565658A1 true EP0565658A1 (fr) 1993-10-20

Family

ID=11360822

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92920465A Withdrawn EP0565658A1 (fr) 1991-10-04 1992-09-30 Utilisation de la verbenone et de ses proprietes anti-elastase dans le traitement de l'emphyseme pulmonaire

Country Status (6)

Country Link
EP (1) EP0565658A1 (fr)
JP (1) JPH06506500A (fr)
AU (1) AU2664492A (fr)
CA (1) CA2097611A1 (fr)
IT (1) IT1251615B (fr)
WO (1) WO1993006823A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
KR101459612B1 (ko) * 2012-06-05 2014-11-07 고려대학교 산학협력단 베르베논 유도체를 함유하는 퇴행성 뇌질환 치료 또는 예방용 조성물
CN113603802B (zh) * 2021-08-24 2022-10-14 华侨大学 一种马鞭草多糖的制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH625197A5 (en) * 1976-06-03 1981-09-15 Buskine Sa Process for preparing verbenone, myrtenal and pinocarveol
EP0491812A4 (en) * 1989-09-14 1992-11-04 Australian Commercial Research & Development Limited Drug delivery compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9306823A1 *

Also Published As

Publication number Publication date
JPH06506500A (ja) 1994-07-21
ITMI912652A0 (it) 1991-10-04
IT1251615B (it) 1995-05-17
AU2664492A (en) 1993-05-03
WO1993006823A1 (fr) 1993-04-15
ITMI912652A1 (it) 1993-04-04
CA2097611A1 (fr) 1993-04-04

Similar Documents

Publication Publication Date Title
Giraldi et al. Antitumour action of rhodium (I) and iridium (I) complexes
Qiu et al. Auricularia auriculajudae polysaccharide-cisplatin complexes conjugated with folic acid as new tumor targeting agents
US5922689A (en) Cisplatin analogs for cancer treatment
EP0565658A1 (fr) Utilisation de la verbenone et de ses proprietes anti-elastase dans le traitement de l'emphyseme pulmonaire
WO1998008831A1 (fr) Traitement preventif ou curatif de la maladie d'alzheimer
JP3084062B2 (ja) ２―フェニル―１，２―ベンズイソセレナゾール―３（２ｈ）―オンの利用法
EP0338092A1 (fr) Agent anti-vih
JP4235111B2 (ja) 超分子カルボプラチン誘導体、その製造方法、活性成分としてその誘導体を含有する薬学的組成物およびその使用
US3839317A (en) Digoxin complexes
EP0578643A1 (fr) Compose et composition pharmaceutique utilises dans le traitement de calculs d'oxalate de calcium
CN115919884B (zh) 一种可掩盖橄榄苦苷苦味的橄榄苦苷-多糖复合物
JPS6183125A (ja) 癌転移阻害剤
RU2784809C2 (ru) Комбинированный продукт, содержащий дициклоплатин, и способ его получения и применения
JPH05112596A (ja) ブフアリンおよびブフアジエノリドを有効成分とす医薬
XU et al. Study on the mechanism of astragalus glycyrrhiza decoction regulating SIRT1/FOXO1 pathway to prevent QT interval prolongation induced by arsenic trioxide based on metabolomics
JP2001253823A (ja) Ｈｉｖ遺伝子発現抑制剤
CN106188129A (zh) 一种染料木素氧钒配合物及其组合物和医用用途
Sartori et al. Early and late hyperferremia during cisplatin chemotherapy
CN102727867A (zh) 一种抗肿瘤用药物组合物及应用、试剂盒及包装件
Sieradzan et al. Comparative effects of cefoxitin and cefotetan on vitamin K metabolism
JPS6357519A (ja) 発癌プロモ−タ−抑制剤
JP2016145175A (ja) アミロイド線維の形成を抑制する抑制剤、アミロイド線維を分解する分解剤、神経変性疾患の予防、治療および／または進展抑制のための医薬、ならびに、抑制剤および分解剤の製造方法
JP2001335503A (ja) ラジカル消去用医薬品
JPS6054320A (ja) 腎疾患治療剤
JPH1129465A (ja) 抗潰瘍剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17P Request for examination filed

Effective date: 19930922

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: FLARER S.A. PHARMACEUTICAL FINE CHEMICALS

17Q First examination report despatched

Effective date: 19980224

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990814